KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV Stock Report

Market Cap: US$499.5m

KalVista Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:KALV Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Nov 24BuyUS$12,000,000Frazier Life Sciences Management, LPCompany1,200,000US$10.00
28 Mar 24SellUS$14,905,154TCG Crossover Management, LLCCompany1,355,014US$11.00
20 Feb 24BuyUS$999,988Frazier Life Sciences Management, LPCompany65,573US$15.25
16 Feb 24SellUS$13,151,726TCG Crossover Management, LLCCompany877,125US$16.22
14 Feb 24SellUS$598,661Christopher YeaIndividual39,886US$15.01
14 Feb 24SellUS$422,827Edward FeenerIndividual28,171US$15.01
14 Feb 24SellUS$875,883Thomas CrockettIndividual58,356US$15.01
14 Feb 24SellUS$613,205Benjamin PalleikoIndividual40,855US$15.01
08 Feb 24BuyUS$1,257,829VR Adviser, LLCCompany86,048US$14.74
30 Jan 24BuyUS$1,274,793VR Adviser, LLCCompany88,099US$14.47
25 Jan 24BuyUS$89,492VR Adviser, LLCCompany7,030US$12.73
24 Jan 24BuyUS$1,241,685VR Adviser, LLCCompany99,129US$12.55
19 Jan 24BuyUS$1,801,602VR Adviser, LLCCompany143,605US$12.60
16 Jan 24BuyUS$333,779VR Adviser, LLCCompany26,246US$12.73
10 Jan 24BuyUS$1,726,457VR Adviser, LLCCompany137,700US$12.67
04 Jan 24BuyUS$720,543VR Adviser, LLCCompany59,369US$12.20
29 Dec 23BuyUS$6,465,650VR Adviser, LLCCompany519,017US$12.50
12 Dec 23BuyUS$2,972,278Frazier Life Sciences Management, LPCompany343,435US$9.53

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KALV?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders734,8381.44%
Hedge Funds8,212,00516.1%
VC/PE Firms11,137,59821.8%
Institutions30,988,26360.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.1%.

Top Shareholders

Top 25 shareholders own 106.55% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.5%
VR Adviser, LLC
6,249,731US$72.2m0%2.81%
11.3%
Frazier Life Sciences Management, LP
4,887,867US$56.5m32.5%1.85%
10%
Tang Capital Management, LLC
4,321,547US$50.0m2.43%3.01%
9.75%
Suvretta Capital Management, LLC
4,212,005US$48.7m0.48%1.42%
9.26%
Vestal Point Capital, LP
4,000,000US$46.2m73.9%3.04%
7.81%
Capital Research and Management Company
3,374,064US$39.0m4.54%no data
7.09%
BlackRock, Inc.
3,062,319US$35.4m3.98%no data
4.98%
The Vanguard Group, Inc.
2,150,527US$24.9m8.03%no data
3.68%
Tavistock Life Sciences
1,590,000US$18.4m0%0.97%
3.44%
Emerald Advisers, LLC
1,486,968US$17.2m26.7%0.29%
3.29%
Adage Capital Management, L.P.
1,419,792US$16.4m-30.7%0.02%
3.01%
Great Point Partners, LLC
1,299,503US$15.0m-2.92%4.49%
2.94%
State Street Global Advisors, Inc.
1,271,609US$14.7m68.1%no data
2.08%
BioImpact Capital LLC
896,915US$10.4m1.7%1.35%
1.92%
Geode Capital Management, LLC
830,984US$9.6m3.07%no data
1.67%
Dafna Capital Management, LLC
723,678US$8.4m-10.3%1.71%
1.41%
Woodline Partners LP
608,253US$7.0m304%0.05%
1.4%
Dimensional Fund Advisors LP
607,036US$7.0m13.5%no data
1.33%
Silverarc Capital Management, LLC
574,558US$6.6m2.44%1.25%
1.29%
Saturn V Capital Management LP
556,489US$6.4m-50.7%2.14%
1%
Schroder Investment Management Limited
431,232US$5.0m-7.86%no data
0.89%
Medical Strategy GmbH, Asset Management Arm
382,666US$4.4m0%0.21%
0.88%
Northern Trust Global Investments
379,375US$4.4m14%no data
0.87%
Jefferies Financial Group Inc.,Asset Management Arm
375,000US$4.3m114%0.17%
0.82%
First Turn Management, LLC
355,000US$4.1m-66.5%0.54%